Application of 18F-SSTR2 Antagonist PET/CT in Neuroendocrine Tumors
Diagnostic Value of SSTR2 Antagonist PET/CT Molecular Imaging in Neuroendocrine Tumors
This study aims to evaluate the safety, distribution in normal organs, radiation dose, and diagnostic value of 18F-labeled somatostatin receptor subtype 2 (SSTR2) antagonist PET/CT imaging. Healthy volunteers will undergo imaging to assess tracer distribution and radiation exposure. Patients with pathologically confirmed grade 1 or 2 neuroendocrine tumors will undergo SSTR2 antagonist and 18F-octreotide PET/CT within 1 week to compare tumor detection and tracer uptake. Selected patients will also receive succinylated gelatin or amino acids before antagonist imaging to assess their effects on kidney and tumor uptake. Imaging findings will be compared with pathological results, SSTR2 expression, and clinical follow-up data.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Xin Liu, M.D.
- 电话号码:13269997223
- 邮箱:liux0077@163.com
学习地点
-
-
Chao Yang
-
Beijing、Chao Yang、中国、100021
- 招聘中
- National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
-
接触:
- Xin Liu, M.D.
- 电话号码:13269997223
- 邮箱:liux0077@163.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Written informed consent and ability to complete imaging and follow-up.
- Healthy volunteers: aged 18-70 years and in good health.
- Patients: pathologically confirmed grade 1-2 neuroendocrine tumors without other malignancy history.
Exclusion Criteria:
- Pregnancy or breastfeeding; planned pregnancy in healthy volunteers.
- Severe liver or kidney dysfunction; severe heart or lung dysfunction in healthy volunteers.
- Relevant drug or tracer allergy in healthy volunteers.
- Inability to lie flat for 30 minutes or complete imaging.
- Other conditions deemed unsuitable by the investigator.
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:SSTR2 Antagonist PET/CT Imaging
Participants will receive an intravenous injection of an 18F-labeled SSTR2 antagonist (0.1-0.15 mCi/kg), followed by PET/CT imaging approximately 60 minutes later. Healthy volunteers will be assessed for normal-organ tracer distribution and radiation dose. Patients with neuroendocrine tumors will also undergo 18F-octreotide PET/CT within 1 week to compare lesion detection and tracer uptake. In the renal protection substudy, patients will receive succinylated gelatin or amino acids 30 minutes before antagonist administration. |
18F-SSTR2 Antagonist was injected into the patients before the PET/CT scans |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Lesion Detection Rates of SSTR2 Antagonist PET/CT Versus 18F-Octreotide PET/CT
大体时间:Paired PET/CT scans within 1 week, with lesion confirmation during follow-up of up to 2 months.
|
Lesion detection rates will be compared between 18F-labeled SSTR2 antagonist PET/CT and 18F-octreotide PET/CT in patients with neuroendocrine tumors. Pathology, conventional imaging, and clinical follow-up findings will serve as the reference for lesion confirmation. |
Paired PET/CT scans within 1 week, with lesion confirmation during follow-up of up to 2 months.
|
合作者和调查者
调查人员
- 学习椅:Xuejuan Wang, M.D.、Chinese Academy of Medical Sciences
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- NCC4568
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.